原发性肿瘤是否适合生物标志物引导的转移性尿路上皮癌治疗？ - Suppr

Suppr

超能文献

Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?

作者信息

Scholtes Mathijs P, van Leenders Geert J L H, Robbrecht Debbie G J, Boormans Joost L, Zuiverloon Tahlita C M

机构信息

Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

出版信息

Transl Androl Urol. 2024 Aug 31;13(8):1341-1345. doi: 10.21037/tau-24-112. Epub 2024 Aug 26.

DOI:10.21037/tau-24-112

PMID:39280671

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11399036/

Abstract

摘要

相似文献

Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?原发性肿瘤是否适合生物标志物引导的转移性尿路上皮癌治疗？

Transl Androl Urol. 2024 Aug 31;13(8):1341-1345. doi: 10.21037/tau-24-112. Epub 2024 Aug 26.

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.分子尿路上皮肿瘤细胞亚型在转移进化过程中保持稳定。

Eur Urol. 2024 Apr;85(4):328-332. doi: 10.1016/j.eururo.2023.03.020. Epub 2023 Apr 6.

Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.程序性细胞死亡配体 1 的表达作为一线免疫检查点抑制剂与化疗治疗转移性尿路上皮癌患者的预测性生物标志物：系统评价和荟萃分析。

Eur Urol Focus. 2022 Jan;8(1):152-159. doi: 10.1016/j.euf.2021.01.003. Epub 2021 Jan 27.

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.通过对循环肿瘤 DNA 的全面基因组分析来鉴定转移性尿路上皮癌。

Cancer. 2018 May 15;124(10):2115-2124. doi: 10.1002/cncr.31314. Epub 2018 Mar 8.

Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites.在尿路上皮癌中，PD-L1 与致癌受体酪氨酸激酶 HER2 和 cMET 的低共表达与原发和转移部位之间的不一致表达相关。

Urol Oncol. 2023 Aug;41(8):357.e23-357.e29. doi: 10.1016/j.urolonc.2023.05.012. Epub 2023 Jun 7.

Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.全面分子特征分析揭示转移性尿路上皮癌的基因组和转录组亚型。

Eur Urol. 2022 Apr;81(4):331-336. doi: 10.1016/j.eururo.2022.01.026. Epub 2022 Jan 25.

Clinical and molecular correlates of response to immune checkpoint blockade in urothelial carcinoma with liver metastasis.肝转移尿路上皮癌中免疫检查点阻断反应的临床和分子相关性。

Cancer Immunol Immunother. 2022 Nov;71(11):2815-2828. doi: 10.1007/s00262-022-03204-6. Epub 2022 Apr 20.

The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.转移性尿路上皮癌一线靶向治疗的快速演变格局：一项系统综述

Oncologist. 2021 Aug;26(8):e1381-e1394. doi: 10.1002/onco.13827. Epub 2021 Jun 11.

Biomarkers of Response to Anti-NECTIN4 Antibody-Drug Conjugate Enfortumab Vedotin in Urothelial Cancer.尿路上皮癌中抗NECTIN4抗体药物偶联物恩诺单抗反应的生物标志物

Eur Urol Focus. 2024 Mar;10(2):224-226. doi: 10.1016/j.euf.2024.04.001. Epub 2024 Apr 16.

Treatment with opioids in patients with locally advanced or metastatic urothelial carcinoma and matched non-cancer controls.局部晚期或转移性尿路上皮癌患者与匹配的非癌症对照患者使用阿片类药物治疗。

Urol Oncol. 2022 Sep;40(9):411.e9-411.e18. doi: 10.1016/j.urolonc.2022.06.013. Epub 2022 Aug 1.

本文引用的文献

Associations of TACSTD2/TROP2 and NECTIN-4/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts.TACSTD2/TROP2 和 NECTIN-4/NECTIN-4 与两个晚期膀胱癌队列中分子亚型、PD-L1 表达和 FGFR3 突变状态的关联。

Histopathology. 2024 Apr;84(5):863-876. doi: 10.1111/his.15130. Epub 2024 Jan 9.

Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer.TROP-2（TACSTD2）在膀胱尿路上皮癌及其他类型癌症中的免疫组化表达。

Oncol Lett. 2023 Oct 23;26(6):527. doi: 10.3892/ol.2023.14114. eCollection 2023 Dec.

Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.厄达替尼与化疗用于晚期或转移性尿路上皮癌。

N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21.

Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".致编辑的信：关于“分子尿路上皮肿瘤细胞亚型在转移演变过程中保持稳定”一文

World J Urol. 2023 Oct;41(10):2869-2870. doi: 10.1007/s00345-023-04544-3. Epub 2023 Jul 29.

Re: Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020.回复：亚历山大·考克斯、尼克拉斯·克吕珀、约翰内斯·施泰因等人。分子尿路上皮肿瘤细胞亚型在转移演变过程中保持稳定。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2023.03.020 。

Eur Urol. 2023 Aug;84(2):e50. doi: 10.1016/j.eururo.2023.04.039. Epub 2023 May 31.

Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution.分子尿路上皮肿瘤细胞亚型在转移进化过程中保持稳定。

Eur Urol. 2024 Apr;85(4):328-332. doi: 10.1016/j.eururo.2023.03.020. Epub 2023 Apr 6.

Genomic heterogeneity as a barrier to precision oncology in urothelial cancer.基因组异质性是膀胱癌精准肿瘤学的障碍。

Cell Rep. 2022 Dec 20;41(12):111859. doi: 10.1016/j.celrep.2022.111859.

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.膜层粘连蛋白 4 的表达在尿路上皮癌转移过程中经常下降，并与恩福妥单抗 vedotin 的耐药性相关。

Clin Cancer Res. 2023 Apr 14;29(8):1496-1505. doi: 10.1158/1078-0432.CCR-22-1764.

Spatial Immunephenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition.远处转移而非配对原发性尿路上皮癌的空间免疫表型可预测对免疫检查点抑制的反应。

Eur Urol. 2023 Feb;83(2):133-142. doi: 10.1016/j.eururo.2022.10.020. Epub 2022 Nov 10.

TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells.TROP2 表达横跨尿路上皮癌的分子亚型和恩福妥珠单抗耐药细胞。

Eur Urol Oncol. 2022 Dec;5(6):714-718. doi: 10.1016/j.euo.2021.11.005. Epub 2022 Feb 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验